Search

Working smarter not harder: How to transform eyecare delivery in the United Kingdom (part 1)

Are we doing enough to meet the current demands on ophthalmic services? In part one of a two-part series (see Part 2 here), Rosalind Harrison takes a look at how efficiency has been improved in eyecare services in the US....

What’s new in glaucoma? Clinical trials drive practice changes, surgical advancements gather pace

Rod McNeil reviews the latest developments in the treatment of glaucoma in the UK. Primary open-angle glaucoma (POAG), which accounts for over two-thirds of all glaucoma cases, has an estimated UK prevalence in 2017 of approximately 2% of people over...

Improved efficacy expected with second-generation microinvasive glaucoma surgery (MIGS) devices

Microinvasive surgical approaches to primary open-angle glaucoma (POAG) offer minimally traumatic options for effective intraocular pressure (IOP) reduction in appropriately selected glaucoma patients. Increases in laser trabeculoplasty rates and wider adoption of glaucoma drainage device filtration procedures, together with the...

Building leaders for eye care in Africa: the COECSA-RCOphth VISION 2020 LINK

The VISION 2020 LINK [1] between the College of Ophthalmology of Eastern, Central and Southern Africa (COECSA) and the Royal College of Ophthalmologists (RCOphth) has been building leaders of eye care in Africa since 2008, when a Memorandum of Understanding...

Optometrist found guilty of manslaughter

To start our new Optometry section, editor Janet Pooley takes a look at the tragic death of Vincent Barker and asks what lessons can be learned. In August, Optometrist Honey Rose was found guilty of the manslaughter of eight-year-old Vincent...

Gene therapy for inherited retinal disease: the Manchester Ocular Gene Therapy Group MDT service

The authors describe the process set up in Manchester for the optimum delivery and assessment of a new gene therapy treatment for patients with RPE65 IRD. Inherited retinal dystrophies (IRDs) are the second commonest cause of severe visual impairment in...

Do patient demographics influence AMD clinic attendance during COVID-19 lockdown?

The authors assess the impact of the COVID-19 pandemic on adherence to scheduled clinic appointments among age-related macular degeneration patients in a clinic in North Wales. The COVID-19 pandemic has significantly affected the population, affecting economic and social wellbeing, whilst...

Fight for Sight to maximise impact by funding solutions-focused research in priority eye conditions

Fight for Sight aims to stop sight loss by funding pioneering research. Rod McNeil takes a look at the Primer Fellowship Awards programme, which provides funding for up to £60,000 for individuals to undertake vision-related research for one year. Among...

Introduction of the Mydriasert insert at the Manchester Royal Eye Hospital

The authors report on a study to examine the effects of the Mydriasert insert on time, effects, patient comfort and tolerability at Manchester Royal Eye Hospital. Mydriasert is an insoluble ophthalmic insert indicated for mydriasis prior to ophthalmic surgery, which...

Surgical options for the treatment of hyperopia

The modern refractive surgeon has a variety of options available to treat patients with hyperopia who wish to be independent of spectacles and contact lenses. Unlike in low myopia where presbyopic patients may have the ability to see well for...

Intravitreal injections delivered by ophthalmic clinical nurse specialists

Intravitreal injections of the anti-vascular endothelial growth factor (anti-VEGF) agent ranibizumab, for the treatment of wet age-related macular degeneration (AMD) was approved by National Institute for Health & Care Excellence (NICE) in 2008 [1]. The Manchester Royal Eye Hospital (MREH),...